key: cord-0732700-1tiupejr authors: Marcolino, Milena S.; Pires, Magda C.; Ramos, Lucas Emanuel F.; Silva, Rafael T.; Oliveira, Luana M.; Carvalho, Rafael L.R.; Mourato, Rodolfo Lucas S.; Sánchez-Montalvá, Adrián; Raventós, Berta; Anschau, Fernando; Chatkin, José Miguel; Nogueira, Matheus C.A.; Júnior, Milton H. Guimarães; Vietta, Giovanna G.; Duani, Helena; Ponce, Daniela; Ziegelmann, Patricia K.; Castro, Luís C.; Ruschel, Karen B.; Cimini, Christiane C.R.; Francisco, Saionara C.; Floriani, Maiara A.; Nascimento, Guilherme F.; Farace, Bárbara L.; Monteiro, Luanna S.; Souza-Silva, Maira V.R.; Sales, Thais L.S.; Martins, Karina Paula M.P.; Borges do Nascimento, Israel J.; Fereguetti, Tatiani O.; Ferrara, Daniel T.M.O.; Botoni, Fernando A.; Etges, Ana Paula B.S.; Boersma, Eric; Polanczyk, Carisi A.; Schwarzbold, Alexandre V.; Maurílio, Amanda O.; Scotton, Ana Luiza B.A.; Weber, André P.; Costa, André S.M.; Glaeser, Andressa B.; Madureira, Angélica Aparecida C.; Bhering, Angelinda R.; de Castro, Bruno Mateus; da Silva, Carla Thais C.A.; Ramos, Carolina M.; Gomes, Caroline D.; de Carvalho, Cíntia A.; Silveira, Daniel V.; Cezar, Edilson; Pereira, Elayne C.; Kroger, Emanuele Marianne S.; Vallt, Felipe B.; Lucas, Fernanda B.; Aranha, Fernando G.; Bartolazzi, Frederico; Crestani, Gabriela P.; Bastos, Gisele A.N.; Madeira, Glícia Cristina de C.; Noal, Helena Carolina; Vianna, Heloisa R.; Guimarães, Henrique C.; Gomes, Isabela M.; Romero, Israel M.; Batista, Joanna D.L.; de Alvarenga, Joice C.; Guimarães, Júlia D.S.S.; de Morais, Júlia D.P.; Rugolo, Juliana M.; Pontes, Karen Cristina J.R.; dos Santos, Kauane Aline M.; de Oliveira, Leonardo S.; Pinheiro, Lílian S.; Pacheco, Liliane S.; Sousa, Lucas de D.; Couto, Luciana S.F.; Kopittke, Luciane; de Moura, Luis Cesar S.; Santos, Luisa Elem A.; Cabral, Máderson A.S.; Souza, Maíra D.; Tofani, Marcela G.T.; Carneiro, Marcelo; Ferreira, Maria Angélica P.; Bicalho, Maria Aparecida C.; Lima, Maria Clara P.B.; Godoy, Mariana F.; Cardoso, Marilia M.A.; Figueiredo, Meire P.; Sampaio, Natália C.S.; Rangel, Natália L.; Crespo, Natália T.; de Oliveira, Neimy R.; Assaf, Pedro L.; Martelli, Petrônio José de L.; Almeida, Rafaela S.C.; Martins, Raphael C.; Lutkmeier, Raquel; Valacio, Reginaldo Aparecido; Finger, Renan G.; Cardoso, Ricardo B.; Pozza, Roberta; Campos, Roberta X.; Menezes, Rochele M.; de Abreu, Roger M.; Silva, Rufino de F.; Guimarães, Silvana M.M.; Araújo, Silvia F.; Pereira, Susany Anastácia; Oliveira, Talita F.; Kurtz, Tatiana; de Oliveira, Thainara C.; Araújo, Thaíza Simônia M.A.; Diniz, Thulio Henrique O.; dos Santos, Veridiana B.; Gomes, Virginia Mara R.; do Vale, Vitor Augusto L.; Ramires, Yuri C. title: ABC(2)-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores date: 2021-07-24 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.07.049 sha: 3aeb99544bba3b9487508ac8870e91ae30e7a210 doc_id: 732700 cord_uid: 1tiupejr OBJECTIVES: The majority of available scores to assess mortality risk of coronavirus disease 19 (COVID-19) patients in the emergency department have high risk of bias. Therefore, our aim was to develop and validate a score at hospital admission for predicting in-hospital mortality in COVID-19 patients, and to compare this score with other existing ones. METHODS: Consecutive patients (≥18 years) with confirmed COVID-19 admitted to the participating hospitals were included. Logistic regression analysis was performed to develop a prediction model for in-hospital mortality, based on the 3978 patients admitted between March-July, 2020. The model was validated in the 1054 patients admitted during August-September, as well as in an external cohort of 474 Spanish patients. RESULTS: Median (25th-75th percentile) age of the model-derivation cohort was 60 (48-72) years, and in-hospital mortality was 20.3%. The validation cohorts had similar age distribution and in-hospital mortality. Seven significant variables were included in the risk score: age, blood urea nitrogen, number of comorbidities, C-reactive protein, SpO(2)/FiO(2) ratio, platelet count and heart rate. The model had high discriminatory value (AUROC 0.844, 95% CI 0.829 to 0.859), which was confirmed in the Brazilian (0.859 [95% CI 0.833 to 0.885]) and Spanish (0.894 [95% CI 0.870 to 0.919]) validation cohorts, and displayed better discrimination ability than other existing scores. It is implemented in a freely available online risk calculator (https://abc2sph.com/). CONCLUSIONS: We designed and validated an easy-to-use rapid scoring system based on characteristics of COVID-19 patients commonly available at hospital presentation, for early stratification for in-hospital mortality risk of patients with COVID-19. Coronavirus disease 2019 is still the main global health, social and economic challenge, overwhelming health care systems in many countries and heavily burdening others. 1,2 Case rates continue to rise, and some hospitals are nearly at their full capacity of intensive care unit beds. The emergence of the new variants of SARS-CoV-2 in England, South Africa, Brazil and India, with very high viral growth, more transmissible, less detectable with the RT-PCR technique or deadlier than the wild-type SARS-CoV-2 and evidence of lower vaccine efficacy, is currently a cause of huge concern 3-6 . Fast and efficient assessment of prognosis of the disease is needed to optimize the allocation of health care and human resources, to empower early identification and intervention of patients at higher risk of poor outcome. A proper assessment tool will guide decision making to develop an appropriate plan of care for each patient 7 . In this context, rapid scoring systems, which combine different variables to estimate the risk of a poor outcome, may be extremely helpful for quick and effective assessment of those patients in the emergency department 8 . Although different scores have been proposed to assess prognosis in COVID-19 patients, the majority of them lack benefit to clinical decision making, and there is a lack of reliable prognostic prediction models 9, 10 . Most scores were developed from small cohorts, at high risk for bias, with selected study samples and relatively few outcome events, without clear details of model derivation and validation, as well as unclear reporting on intended use 11- hospital mortality in patients with COVID-19, able to discriminate high vs non-high risk patients. Additionally, we aimed to compare this score with other existing ones. This study is part of the Brazilian COVID-19 Registry, an ongoing multicenter observational study described elsewhere 17 , and a collaboration with Vall d'Hebron University Hospital, in Barcelona, Spain, for independent external validation. The Brazilian COVID-19 Registry is being conducted according to a predefined protocol, in 36 Brazilian hospitals, located in 17 cities, from five Brazilian states. Model development, validation and reporting followed guidance from the Transparent Material) 18, 19 . Consecutive adult patients (≥18 years-old) with laboratory-confirmed COVID -19 20 admitted to the participating hospitals from March 1 to September 30, 2020 were enrolled. Patients who were transferred between hospitals and admission data from the first hospital (as we aimed to develop a score to be used in the first assessment) or the last hospital was not available were excluded (Table S1 ), as well those who were admitted for other reasons and developed COVID-19 symptoms during their stay (Figure 1 ). Demographic information, clinical characteristics, laboratory and outcome data were collected from the medical records by using a prespecified case report form applying Research Electronic Data Capture (REDCap) tools 21, 22 . Data were collected by trained hospital staff or interns. A detailed data management plan (DMP) was developed and provided to all participating centers, and an online DMP training was mandatory before local research personnel were allowed to start collecting study data 23 . We undertook comprehensive data quality checks to ensure high quality. A code was developed in R software to identify values likely related to data entry errors for vital signs and laboratory variables, based on expert-guided rules. Data were sent to each center for checking and correction. All variables used to calculate the risk score were obtained at hospital admission. A set of potential predictor variables for in-hospital mortality was selected a priori, as recommended 19 , taking into account the evidence in literature of association with worse prognosis in patients with COVID-19 or pneumonia, and availability of predictor measurement at the time the model would be used, i.e., hospital admission 11 . All laboratory tests were performed at the discretion of the treating physician. Imaging test results were not included, as X-ray and CT scan are not always performed at patient admission and their interpretation involve subjective judgement. Candidate predictor variables which were not available for at least two thirds of patients within the derivation cohort (more than one third of missing data) were excluded. Continuous variables were summarized using medians and interquartile ranges (IQR), whereas counts and percentages were used for categorical variables. We reported 95% confidence intervals, and a p-value less than 0.05 was considered statistically significant. Statistical analysis was performed with R software (version 4.0.2) with the mgcv, finalfit, mice, glmnet, pROC, rms, rmda, and psfmi packages. Considering missing at random after analyzing missing data patterns, multiple imputation with chained equations (MICE) was used to handle missing values on candidate variables (outcomes were not imputed). Mortality outcome was used as a predictor in MICE in the derivation dataset, but not in the validation dataset. We used predictive mean matching (PMM) method for continuous predictors and polytomous regression for categorical variables (two or more unordered levels). The results of ten imputed datasets, each with ten iterations, were combined following Rubin's rules 24 . Patients who were admitted before July 31 were included in the development cohort ( Figure S1 ). We conducted predictor selection based on clinical reasoning and literature review before modeling. Generalized additive models (GAM) were used to examine the relationships between in-hospital mortality and continuous (through penalized thin plate splines) and categorical (as linear components) predictors. During this stage, variable selection was based on D1-(multivariate Wald test) and D2-statistic (pools test statistics from the repeated analyses). Subsequently, for an easier application of the risk score model at bedside, continuous variables were categorized based on widely accepted cut points, current evidence and/or categories defined in stablished scores for pneumonia and sepsis. Lastly, we used least absolute shrinkage and selection operator (LASSO) logistic regression to derive the mortality score by scaling the (L1 penalized) shrunk coefficients. The penalty parameter λ in LASSO was chosen using 10-fold cross-validation methods based on mean squared error criterion. Risk groups were proposed based on predicted probabilities: low risk ( < 6.0%), intermediate risk (6.0 -14.9%), high risk (15.0 -49.9%), and very high risk (≥ 50.0%), as recommended by TRIPOD Guidelines 18 . Risk strata was based on other scores 25 . We performed an external (temporal) validation analysis using patients who were admitted from August 1 to September 30, 2020. Independent external validation was also performed in a cohort of patients from Vall d'Hebron University Hospital, in Barcelona, Spain, admitted from March 1 to May 31, 2020 26 . Inclusion and exclusion criteria were the same as the beforementioned ones. All patients included were followed for at least 28 days. The aforementioned methods for data imputation were used. We evaluated overall performance using Brier score 27 . Calibration was assessed graphically by plotting the predicted mortality probabilities against the observed mortality, testing intercept equals zero and slope equals one. The area under the receiver operating characteristic curve (AUROC) described model's discrimination. Confidence intervals (95% CI) 23 for AUROC were obtained through 2000 bootstrap samples. Positive and negative predictive values of the derived risk groups were calculated. The developed model was compared within the validation cohort with existing scores. These scores were identified through a literature search of Medline, medRxiv and BioRxiv, with no language or date restrictions, using the search terms "COVID-19," "COVID", "SARS-CoV-2," "coronavirus" combined with "score" and "mortality". The last search was performed on November 19, 2020. Two authors independently performed article selection and data extraction. Additionally, we also included established scores for pneumonia and sepsis [28] [29] [30] [31] [32] . From the set of identified scores, we selected those which with predictors were available within the database and had accessible methods for calculation. Model comparisons were performed using AUROC and decision curve analysis. Risk score calculator was developed in Javascript, using the Svelte framework while the website was developed in R language (blogdown package). The derivation cohort included 3978 patients, from 267 cities in Brazil ( Figure 2 ). Median age was 60 [IQR, years, 53.8% were male, 70.1% had at least one comorbidity and 20.3% died during hospitalization. Table 1 shows demographic, clinical characteristics and laboratory findings for the derivation and validation datasets. Thirty-six potential predictor variables were identified (Table S2) . Number of comorbidities was created as a composite of ten individual comorbidities shown to have prognostic impact in COVID-9 (hypertension, diabetes mellitus, obesity, coronary artery disease, heart failure, atrial fibrillation or flutter, cirrhosis, chronic obstructive pulmonary disease, cancer and previous stroke) 33,34 , as in other scores 25, 35 . Twelve variables were excluded due to the excessive number of missing values, two for high collinearity, and one was not recorded within database. Inotrope use was combined with blood pressure. Therefore, 20 variables were tested. Through generalized additive model (GAM), a combination of seven variables was selected as the best predictor of in hospital mortality (Table S3) . For an easier application to the risk score model at bedside, continuous selected predictors were categorized for LASSO logistic regression. All categories were defined a priori, based on widely accepted cut points, current evidence and/or categories defined in stablished rapid scoring systems from pneumonia and sepsis 19 . All variables were statistically significant predictors for in hospital mortality (Table S4 and Figure S2 ). Shrunk coefficients were scaled to provide a prognostic index and we denoted it as the ABC 2 -SPH risk score ( Table 2 ). The sum of the prediction scores ranges between 0 and 20, with a high score indicating higher risk of in-hospital mortality. Risk groups were proposed based on predicted probabilities (Table 3) : low risk (0-1 score, observed in hospital mortality 2.0%), intermediate risk (2-4 score, 11 .4%), high risk (5-8 score, 32.0%), and very high risk (≥ 9 score, 69.4%). Subject-specific risks can be assessed using the developed ABC 2 -SPH risk score Web-based calculator (https://abc2sph.com/), freely available to the public, and it can also be assessed through infographics ( Figure S3 ). As well as GAM and LASSO, ABC 2 -SPH risk score showed good overall performance (Brier score: 0.114) and good discrimination (AUROC equal 0.842; 95% CI 0.840-0.843) within the derivation cohort (Table 4) . A total of 1054 patients were included in the validation cohort. Median age was 62 (IQR 48-73) years, 55.2% were male, 70.7% had at least one comorbidity and 19.7% died during hospitalization. The distribution of patients across range ABC 2 -SPH score in derivation and validation cohorts are presented in Figure 3 . We observed ABC 2 -SPH risk score had AUROC=0.859 (95% CI 0.833 to 0.885), good overall performance (Brier = 0.108) and calibration (slope = 1.138, intercept = 0.114, p-value = 0.184; Figure S4a ) under the validation cohort ( Figure 4 ). The good performance is also demonstrated in sensitivity analyses using complete case data (Table S5) Figure 4 ), good overall performance (Brier = 0.093). Calibration is shown in Figure S4b . The literature search identified 39 scores to predict mortality in COVID-19 patients (Table 5 ). In 36% the derivation cohort was from China, 21% from the United States and none from South America. Based on complete case validation cohort, the ABC 2 -SPH score achieved better discrimination (Table 6, Figure 5a ) than other prediction scoring systems for COVID-19, pneumonia and sepsis (0.85; 95% CI: 0.82 -0.88). Xie's and Zhang's score 7,36,37 showed good discrimination, but the number of complete cases and deaths were relatively small. Considering clinical utility (Figure 5b ), ABC 2 -SPH showed a better performance compared to the three most discriminating scores for in-hospital mortality that were tested in more than 600 patients (4C Mortality Score, A-DROP and CURB-65) 25, 29 . ABC 2 -SPH score is simple, objective, easily available at hospital admission and easily calculated, employing seven well defined and routinely recordable variables. It has shown to be a reliable tool to estimate in-hospital mortality in COVID-19 patients. Model performance compared surpassed other existing scores. The majority of developed scores are limited by methodological bias in development cohorts. Robust models require large sample sizes, which produce more reliable and accurate results 18 . Among the models analyzed for comparison, only 30.8% used a sample with more than 1000 patients, 41.0% used a sample with less than 500 patients, and 41.0% were developed and validated in a sample with less than 100 events. Most of the models we analyzed for comparison (69.2%) did not perform or did not describe whether imputation methods were used for the missing data, therefore, there is a high risk of bias related to the treatment of missing data. The approach of excluding the missing data and performing the analysis with the complete cases can lead to biased results, since the complete cases may not adequately represent the entire original study sample, generating a selection bias 18 . In 43.6% of the analyzed studies, external validation of the developed model was not performed. As the accuracy of a prediction model is always high whether the model is validated on the development cohort used to derive the model only, the assessment of accuracy in those studies may be overoptimistic 18 . Previous studies have observed the variables included in the ABC 2 -SPH score as risk factors for severe COVID-19, what shows that our results are in line with the available evidence. Age and number of comorbidities were reported as independent risk factors for developing severe COVID and mortality in several publications 9, 25, 38 . The strong age gradient per decade after 60 years-old is in line with other series 9, 13 . Aging is associated with a wellknown decline in the adaptive and innate immunity, which plays a major role in the increased susceptibility of infections 39 . It is also related to an increased severity in pro-inflammatory response and increased cytokine production, what is believed to increase patient vulnerability to the unregulated inflammatory response in COVID-19 40 . The number of comorbidities indicates the importance of pre-existing conditions to the severity of COVID-19. Even though comorbidities are age-dependent factors, the number of comorbidities remained as an independent risk factor in the final model. As we aimed to use variables easily available at ED admission of any institution, we opted to evaluate the SpO 2 /FiO 2 ratio (SF ratio), instead of the ratio of arterial oxygen partial pressure over the fraction of inspired oxygen (PaO 2 /FiO 2 ratio), like the COVID-AID score 41 . Arterial blood gas puncture and analysis is an invasive and complex procedure, which may be time consuming for the team. SF ratio was already validated as a substitute for the PaO 2 /FiO 2 ratio in assessing the oxygenation criterion of patients with acute lung injury and acute respiratory distress syndrome 42 . COVID-19 associated hyperinflammation and coagulopathy are correlated to with a wide deviation in various inflammatory markers and hemostasis parameters, and thus these are potential prognostic markers of increased mortality in COVID-19 43, 44 . Consistent with prior studies 45, 46 , we also observed utility of CRP, an acute phase reactor with established prognostic prediction role in intensive care septic and non-septic patients 47, 48 , and thrombocytopenia. The prognostic value of thrombocytopenia in COVID-19 patients has shown in a recent meta-analysis 49 , and it was also included in other scores 9, 45 . The exact explanation is still unknown, and it is probably multifactorial, related to direct infection of bone marrow cells by the virus, resulting in abnormal hematopoiesis; platelet destruction by the immune system; endothelial damage triggering platelet activation, aggregation and microthrombi in the lung; and abnormal platelet defragmentation in the lungs 49 . A recent meta-analysis (16 studies, n=3480) has shown significantly higher levels of Ddimer on admission in patients who died compared to the ones who were discharged 43 . This exam was included as a predictor in different scores 12, 15, 46, 50, 51 . However, the value has to be determined with the same methodology, preferably from the same manufacturer, and this information was not available in any of the studies. A recent publication highlighted confusion and potential for misinformation in reporting D-dimer data in COVID-19 52 Most studies have not reported how they dealt with cases who were transferred between hospitals. As the score is intended to be used at hospital admission, we opted to 29 exclude patients who were transferred between hospitals and admission data from the first hospital was not available, to avoid the possibility the patients were already with critical disease. Blood urea nitrogen elevation was a strong predictor for mortality, what is in line with other scores 25, 53, 54 . Although autopsy studies did not find conclusive evidence of SARS-CoV2 infection in the kidney, some authors hypothesize that the damage may be mediated by direct cytopathic effects of SARS-Cov2 on the kidney tissue, immune-mediated damage due to virusinduced immune complexes, as well as the effects of the inflammatory response, hypoxia and shock [55] [56] [57] . A major strength of the ABC 2 -SPH score is its simplicity, with the use of objective parameters, what helps to reduce inter-user variability, easily available at the emergency department presentation, even in under-resourced settings. The present study followed strict methodological criteria, recommended by TRIPOD 18 checklist and PROBAST 19 , and was based on robust sample of patients with confirmed SARS-CoV-2 infection from 36 hospitals in four Brazilian states, to ensure diversity of the population studied and representativeness of the intended target population. The majority of published scores were developed in China or the US (56.4%) and Europe (25.6%), this is the first study in the Latin American population. Data were obtained by detailed medical chart reviews, and we were able to collect comprehensive data from a large number of patients and follow 98.5% of the patients from admission to discharge or death. Decisions about which predictors to retain in the final model did not rely on potentially biased univariable selection of predictors. They were based on clinical reasoning, previous evidence from other cohorts and systematic reviews on prognostic factors for COVID-19 patients and availability of predictor measurement at hospital admission 18 . With regards to study limitations, due to the pragmatic study design, laboratory tests were performed at the discretion of the treating physician, and we did not have a full dataset on all laboratory parameters of interest available. Some laboratory parameters, which proved to be of prognostic relevance in other studies, were not available for at least 2/3 of patients in our sample. Therefore, we cannot rule out that variables with a higher proportion of missing data would have had a significant impact on mortality prediction. Additionally, we were unable to assess the predictive ability of some scores, as some required variables were not available. In the Spanish validation cohort, true mortality risk was somewhat underestimated in very high-risk patients. The majority of those patients came from the beginning of the pandemic, and at that time doctors used to admit patients earlier in the course of the disease. Therefore, patients were admitted in a less severe condition than Brazilian ones, what can be inferred from the difference in SF ratio. This is probably the explanation for the underestimation in very high-risk patients among the Spanish cohort. Even with this difference, the score was able to show very good discrimination to differentiate patients with high vs. non-high risk, what is the main goal in using such scores. ABC 2 -SPH score may be very useful in a real-world setting, to provide healthcare practitioners the decision support that is needed to help them better identify and prioritize the care of patients who have the higher risk of death. Its development and validation followed strict methodological criteria, and the score fulfils the characteristics of an ideal score 58 . It can be used in all emergency departments, regardless of the level of resource settings. The results represent the experience of 36 hospitals in 17 cities in Brazil, and one hospital in Spain, and they are highly relevant to the current pandemic. It can be easily calculated at bedside or could be easily integrated to the electronic medical records for an automatic computation. It may help clinicians to identify high-risk patients from the triage phase, as well as to identify those most appropriate to be enrolled into therapeutic trials, may make possible to expand inclusion 31 criteria through the early identification of patients who may benefit from therapy 59 . It might also be useful to help guiding recommendations for early palliative consultation 60, 61 . Different from what has been mistakenly suggested 25, [62] [63] [64] , the results from this study do not suggest that patients from low-risk group may be discharged for home treatment. No score so far has specifically tested this hypothesis. A recent editorial has highlighted the importance of taking into account the "treatment paradox": patients identified to be at the low risk group were at low risk due to the interventions received in hospital 65 . It must not be interpreted as the risk to a patient if no actions are taken. Sperrin & McMillan counterfactual prediction modelling as a potential solution to minimize bias from treatment paradox 65 . More importantly, due to the treatment paradox, scoring systems developed and validated in inhospital settings cannot be used in outpatient settings without further validation, as it has been mistakenly suggested 66 . We believe that ABC 2 -SPH score may hold potential generalizability for other countries. However, prediction models are population specific and may produce different results in different populations 67 . Considering that thresholds for admission may vary, hospitalized COVID-19 population may be different, the outcome events are different and patient management may be different, further validation (and re-calibration) in different health care settings is recommended. In particular, we learned that our model might underestimate mortality in high-risk individuals. As we opted to develop the score focusing on information available at admission, as this would make it more useful for clinicians, other important factors during hospitalization 32 that may impact prognosis were not included. Further analysis involving these factors are required. ABC 2 -SPH score may help clinicians to make a prompt and reasonable decision to optimize patient management and potentially reduce mortality. However, further prospective studies are needed to investigate whether the use of the score in the emergency department indeed trigger actions that result in reduced complications and hospital mortality. Additionally, due to the rapidly changing nature of the COVID-19 and the disease management, model performance should be monitored closely over time and space 65 . Future studies may also investigate risk factors for mortality among patients who develop COVID-19 symptoms during hospital admission due to other conditions. In conclusion, we developed and validated the ABC 2 -SPH rapid scoring system and a web-based risk calculator. This score, based on age, number of comorbidities, blood urea nitrogen, C-reactive protein, platelet count, peripheral oxygen saturation and oxygen support at admission is an inexpensive tool, showed to objectively and accurately predict in-hospital mortality in COVID-19 patients. It may be used at bedside for earlier identification of inhospital mortality risk and, thus, inform clinical decisions and the assignment to the appropriate level of care and treatment for COVID-19 patients. Ethics approval and consent to participate 33 The study protocol was approved by the Brazilian National Commission for Research Ethics (CAAE 30350820.5.1001.0008). Individual informed consent was waived due to the severity of the situation and the use of deidentified data, based on medical chart review only. For the independent external validation cohort, it was approved by the and Vall d'Hebron University Hospital Research Ethics Committee (PR(AG)183/2020). The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Data are available upon reasonable request. The lead authors (MSM and MCP) had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The lead authors (MSM and MCP) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained. The sponsors had no role in study design; data collection, management, analysis, and interpretation; writing the manuscript; and decision to submit it for publication. MSM and MP had full access to all the data in the study and had responsibility for the decision to submit for publication. We would like to thank the hospitals which are part of this collaboration, for We also thank all the clinical staff at those hospitals, who cared for the patients, and all undergraduate students who helped with data collection. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Marcolino MS, Ziegelmann PK, Souza-Silva MV, et al. Adult patients with confirmed COVID-19 from 11 acute care hospitals in New York, from March 1, 2020 to April 23, 7 2020. Patients were excluded if they were still in the hospital at the study end point with a length of stay less than 7 days; if they were transferred to a hospital outside of the health system and their outcomes were unknown; or if they expired but were not marked as discharged The same as the development cohort from another hospital in New York from March 1, 2020 to May, 7 2020, and all 12 hospitals from April 24, 2020 to May 6, 2020. in the EH Authors reported that clinical datasets were collected when healthcare services were under severe strain. Data extraction sought to ensure consistency and accuracy, but there is missing data in both datasets, and the analysis was complete case based. Sample sizes for development and validation were small, with <100 events. Clinical assessments at admission such as SpO2 were not available in either dataset. The external validation dataset has very different casemix, and only had follow-up to a fixed date (6-39 days). Although the Wuhan cohort includes many people with less severe disease, in the validation cohort most admitted patients are likely to have severe disease. Although the authors reported all variables were included in the model, for most of the included ones the 95% CI of the OR included 1.0 Small sample size for evelopment and validation, <100 events for both cohorst. The amount of missing data differed between the survivor and non-survivor groups. The study included a high population of patients who were severely ill, the authors pointed out there may be a selection bias when identifying the risk factors of Universidade do Sul de Santa Catarina (UNISUL) Lá opera, 401b, Florianópolis, Brazil. Collaborating researcher, SOS Cardio Hospital Mário Rubens Guimarães Montenegro, s/n -UNESP -Campus de Botucatu Universidade Federal do Rio Grande do Sul and Institute for Health Technology Assessment (IATS/ CNPq). Hospital Tacchini. Rua Ramiro Barcelos Hospital Mãe de Deus, Hospital Universitário de Canoas Rio Grande do Sul and Institute for Health Technology Assessment (IATS/ CNPq) Universidade Federal dos Vales do Jequitinhonha e Mucuri -UFVJM. Hospital Head of Value Management Office. Moinhos Research Institute. 910 Ramiro Barcelos Street, 5 floor Internal Medicine Physician and Master's Student. Hospital Metropolitano Odilon Behrens Avenida Professor Alfredo Balena 190 Avenida Professor Alfredo Balena, 190, sala 246 Avenida Professor Alfredo Balena 190 Avenida Professor Alfredo Balena Universidade Federal do Rio Grande do Sul and Institute for Health Technology Assessment (IATS/ CNPq). Rua Ramiro Barcelos, 2359. Prédio 21 | Sala Coordinator of the Institute for Health Technology Assessment (IATS/ CNPq). Rua Ramiro Barcelos, 2359. Prédio 21 | Sala Hospital Universitário de Santa Maria Undergraduate Medical Student. Faculdade Ciências Médicas de Minas Gerais Undergraduate Nursing Student. Faculdade de Ciências Humanas de Curvelo Universidade do Sul de Santa Catarina (UNISUL) Belo Horizonte, Brazil 51 Hospital Santo Antônio. Praça Dr. Márcio Carvalho Lopes Filho Hospital Moinhos de Vento. R. Ramiro Barcelos Hospital Universitário Ciências Médicas. Rua dos Aimorés -2896 Instituto René Rachou-FIOCRUZ Minas Undergraduate Medical Student. Pontífica Universidade Católica de Minas Gerais Universidade Federal dos Vales do Jequitinhonha e Mucuri Hospital de Clínicas de Porto Alegre Gerais -13º andar Universidade Federal de References 1. WHO. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update Fair Allocation of Scarce Medical Resources in the Time of Covid-19 The British variant of the new coronavirus-19 A Troubling New Pattern Among the Coronavirus Variants Genomic characterisation of an emergent SARS CoV-2 lineage in Manaus: preliminary findings COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study Prediction models for COVID-19 clinical decision making Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: An observational cohort study Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal Thrombo-inflammatory features predicting mortality in patients with COVID-19: The FAD-85 score Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients The Implication of Cardiac Injury Score on In-hospital Mortality of Coronavirus Disease Clinical features predicting mortality risk in older patients with COVID-19 Clinical Characteristics and In-Hospital Mortality for COVID-19 Across The Globe Clinical stability and in-hospital mortality prediction in COVID-19 patients presenting to the Emergency Department External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study Prediction models for covid-19 outcomes A Novel Scoring System for Prediction of Disease Severity in COVID-19 Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration Patient Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission Prognostic factors of chest CT findings for ICU admission and mortality in patients with COVID-19 pneumonia Italy, insights of the HOPE COVID-19 registry Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Development and calibration of a simple mortality risk score for hospitalized COVID-19 adults Clinical features of COVID-19 mortality: development and validation of a clinical prediction model Development and validation of prognostic model for predicting mortality of COVID-19 patients in Wuhan ACP risk grade: a simple mortality index for patients with in Wuhan, China. Preprints with The Lancet Respiratory rate (irpm)  90 (mm Hg) operator logistic regression; NA: not applicable; RDW: red blood cell distribution width; PLS: partial least squares RF: Random Forest; SF ratio: SpO 2 /FiO 2 ratio; SVM: support-vector machine; XGBoost: eXtreme Gradient Boosting; WHO: World Health Organization The auhtors reported they were unable to develop a model on COVID-19 patient data due the scarcity of databases that contains this information in sufficient numbers. Based on seconday data, with possibility of misclassifications of predictors (diseases is incorrectly recorded in a patient's history, incorrect recording of influenza or COVID-19, and authors were unable to include some suspected diseases predictors such as BMI/obesity in the analysis due to the inconsistency with which these mesures are collected and reporte across the databases included in the study. Patients may day after 30 days, and this will be recorded as a non-event. Apparently, complete case analysis. Small sample size of both development and validation samples, with <100 events. Too many predictors tested for a small number of events. The authors did not exclude patients transferred from other hospitals (so the assessment was not the first hospital assessment in all patients). Single center study, patients from both derivation and validation sets were from Tongji Hospital, which is one of the hospitals with a high level of medical care in China (the authors reported that some critically ill patients who recovered there might die in other hospitals with suboptimal or typical levels of medical care).AUC: area under the curve; BMI: body mass index; CI: confidence interval; CPOD: chronic obstructive pulmonary disease; CPR: C-reactive protein; CT: computed tomography; DLN: deep learning networks; DM: diabetes mellitus; GFR: glomerular filtration rate; ICU: intensive care unit; LASSO: least absolute shrinkage and selection